Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Express Scripts
Queensland Health
Federal Trade Commission
QuintilesIMS
Merck

Generated: September 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,215,300

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,215,300 protect, and when does it expire?

Patent 8,215,300 protects AFREZZA and is included in one NDA.

This patent has sixty-one patent family members in eighteen countries.

Summary for Patent: 8,215,300
Title:Unit dose cartridge and dry powder inhaler
Abstract: A dry powder inhaler having improved aerodynamic properties for diluting, dispersing, and metering drug particles for increasing the efficiency of pulmonary drug delivery to a patient is described. The inhaler comprises, in general, a housing having an air intake, an air flow-control/check-valve, a mixing section and a mouthpiece. A cartridge loaded with a single dose of medicament can be installed in the mixing section.
Inventor(s): Steiner; Solomon S. (Mount Kisco, NY), Poole; Trent A. (South Amherst, MA), Fog; Per B. (Bedford Hills, NY), Pohl; Roderike (Sherman, CT), Crick; Michael (Middlebury, CT), Feldstein; Robert (Yonkers, NY)
Assignee: MannKind Corporation (Valencia, CA)
Application Number:12/102,625
Patent Claim Types:
see list of patent claims
Delivery; Device; Use;

Drugs Protected by US Patent 8,215,300

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-001 Jun 27, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-002 Jun 27, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-003 Apr 17, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,215,300

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 339981 ➤ Sign Up
Austria 390944 ➤ Sign Up
Australia 2004270204 ➤ Sign Up
Australia 2005201843 ➤ Sign Up
Australia 2009201564 ➤ Sign Up
Australia 2009212849 ➤ Sign Up
Australia 7138000 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Harvard Business School
AstraZeneca
Express Scripts
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.